Corbus Pharmaceuticals Holdings Inc. (CRBP) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $3.92 (-7.23% 1D, market cap $75.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CRBP ranks #638 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CRBP carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, COYA (Coya Therapeutics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $75.8M) and RANI (Rani Therapeutics Holdings Inc. (Class A)) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $76.9M). Among the 5-stock peer group, LFVN leads on earnings multiple (7.5x) while LFVN leads on capital efficiency (29.2% ROIC).
Per CRBP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001595097), Corbus Pharmaceuticals Holdings Inc. generated $238.9M in revenue (+75.1% YoY), -$78.5M in net income, and -$64.5M in free cash flow against $168.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While CRBP currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.92) and Max Pain ($4.12) forces dealer call-delta covering toward $13.52.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Corbus Pharmaceuticals Holdings Inc. (CRBP) dropped -7.23% to $3.92, trading at 2% of its 52-week range ($3.87 – $12.88). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
MarketWatch report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
MarketWatch report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
NORWOOD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that late breaking data f
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that late breaking data from the CRB-913 Canyon-1 Phase 1B study will be
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +75.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CRBP today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CRBP. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Corbus Pharmaceuticals Holdings Inc. (CRBP) ranks #638 by composite RQD confidence (34/100, grade E) and #687 by equity capitalization ($75.7M). Within this direct 5-issuer industry benchmark cohort, LFVN leads on earnings valuation at 7.5x trailing P/E, while LFVN leads on capital efficiency and profitability with 29.2% ROIC and 80.4% gross margin. LFVN currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with CRBP at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CRBP
ACTIVE
Corbus Pharmaceuticals Holdings Inc. | E | 34/100 | — | — | -35.0% | -7.23% | $75.7M | Benchmark Subject |
| COYA Coya Therapeutics Inc. | E | 29/100 | — | — | -35.0% | -10.53% | $75.8M | /coya-vs-crbp → |
| RANI Rani Therapeutics Holdings Inc. (Class A) | E | 30/100 | — | — | -35.0% | -6.47% | $76.9M | /rani-vs-crbp → |
| LFVN Lifevantage Corporation (Delaware) | C+ | 67/100 | 7.5x | 80.4% | 29.2% | -0.17% | $73.9M | /lfvn-vs-crbp → |
| CING Cingulate Inc. | E | 34/100 | — | — | -35.0% | +1.00% | $73.1M | /cing-vs-crbp → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Corbus Pharmaceuticals Holdings Inc. (CRBP) reported GAAP revenue of $238.9M (+75.1% vs. FY2024 revenue of $136.4M , and +89.2% cumulative change since FY2023) , GAAP net income of -$78.5M, operating cash flow of -$64.5M, and free cash flow of -$64.5M (-54.3% YoY). On the balance sheet, CRBP closed FY2025 with $168.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $238.9M | -$78.5M | -$64.5M | -$64.5M | $168.2M | — |
| FY2024 (FY) | 2024-12-31 | $136.4M | -$40.2M | -$41.8M | -$41.8M | $155.9M | — |
| FY2023 (FY) | 2023-12-31 | $126.2M | -$44.6M | -$36.1M | -$36.1M | — | — |
As of 2026-11-03, Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $3.92 (-7.23% 1D, market cap $75.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CRBP ranks #638 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CRBP carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, COYA (Coya Therapeutics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $75.8M) and RANI (Rani Therapeutics Holdings Inc. (Class A)) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $76.9M). Among the 5-stock peer group, LFVN leads on earnings multiple (7.5x) while LFVN leads on capital efficiency (29.2% ROIC).
Per CRBP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001595097), Corbus Pharmaceuticals Holdings Inc. generated $238.9M in revenue (+75.1% YoY), -$78.5M in net income, and -$64.5M in free cash flow against $168.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
CRBP last traded at $3.92 (-7.23% on volume of 674,229 shares), positioning the stock -43.35% below its 50-day simple moving average ($6.92) and -54.31% below its 200-day simple moving average ($8.58). Across its 52-week range of $3.87 to $12.88, CRBP sits at the 0.6% percentile with a 14-day RSI of 22.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($3.43 to $4.41).
Corbus Pharmaceuticals Holdings Inc. (CRBP) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.92 (-7.23% 1D, market capitalization $75.7M).
Corbus Pharmaceuticals Holdings Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..1B. —: a product list, customer identities, or the company's monetization model beyond the absence of reported revenue.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Corbus Pharmaceuticals Holdings Inc. (CRBP) reported $238.9M in annual revenue (up from $136.4M in FY2024, +75.1% YoY) and -$78.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($126.2M revenue, -$44.6M net income) through FY2025, CRBP scaled operating cash flow to -$64.5M and free cash flow to -$64.5M, backed by $168.2M in total assets against $0 in total debt.
— The Butterfly Supply-Chain Graph lists no upstream or downstream dependencies, no sector correlations, and no proprietary signals for CRBP. Investors should note that the absence of mapped links means the source cannot identify 2nd-order bottlenecks; the observation is limited to the fact that the company is classified in Biotechnology: Pharmaceutical Preparations.
Real-time company headlines, analyst actions, and sector developments for Corbus Pharmaceuticals Holdings Inc. (CRBP) • Click "Debate This Headline" to argue it in the Roar Pit below
MarketWatch report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
MarketWatch report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.
NORWOOD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that late breaking data f
Here is why I am bullish on CRBP here at $4.22: The stock trades at $4.22 against a 52-week range of $3.87 to $12.88, and the Macro Regime Fit pillar scores 15 / 20 on a beta of 1.0.. Compare CRBP's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $4.01 are getting bought.
@MultipleCompression Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
I respect the product at Corbus Pharmaceuticals Holdings Inc., but the stock at $4.22 is a different story. Valuation & margin reality check on CRBP at $4.22 before chasing here. FCF yield is 0.0% and RQD sits at 34/100 (E) — why pay up here when you can wait for next quarter's numbers?
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: